Doxorubicin toxicity can be ameliorated during antioxidant L-carnitine supplementation

Oxidative Medicine and Cellular Longevity

Volumn 3, Issue 6, 2010, Pages 428-433

  Alshabanah, Othman A ^a   Hafez, Mohamed M ^a   Al Harbi, Mohamed M ^a   Hassan, Zeinab K ^b   Al Rejaie, Salim S ^a   Asiri, Yosef A ^a   Sayed Ahmed, Mohamed M ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Antioxidant agent; Doxorubicin; Gene expression; Hepatotoxicity; L carnitine

Indexed keywords

ALKALINITY; AMINO ACIDS; GENE EXPRESSION; PEPTIDES; PHOSPHATASES; POLYMERASE CHAIN REACTION;

DOXORUBICIN; GENE EXPRESSION LEVELS; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; GLUTATHIONE S-TRANSFERASES; HEPATOTOXICITY; L-CARNITINE; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

ANTIOXIDANTS;

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; BILIRUBIN; CARNITINE; CATALASE; DOXORUBICIN; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; GLUTATHIONE TRANSFERASE; NITRATE; NITRITE; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; ANTINEOPLASTIC ANTIBIOTIC; ANTIOXIDANT;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG ANTAGONISM; DRUG DOSE COMPARISON; LIVER INJURY; MALE; NONHUMAN; OXIDATIVE STRESS; RAT; TREATMENT DURATION; ANIMAL; BLOOD; GENETICS; METABOLISM; TOXIC HEPATITIS; WISTAR RAT;

RATTUS;

ALANINE TRANSAMINASE; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIOXIDANTS; BILIRUBIN; CARNITINE; CATALASE; DOXORUBICIN; DRUG-INDUCED LIVER INJURY; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; GLUTATHIONE TRANSFERASE; MALE; RATS; RATS, WISTAR; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 79951534492     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.4161/oxim.3.6.14416     Document Type: Article

References (57)

1. Sayed-Ahmed MM, Al-Shabanah OA, Hafez MM, Aleisa AM, Al-Rejaie SS. Inhibition of gene expression of heart fatty acid binding protein and organic cation/carnitine transporter in doxorubicin cardiomyopathic rat model. Eur J Pharmacol 2010; 640:143-9.
2. Yagmurca M, Bas O, Mollaoglu H, Sahin O, Nacar A, Karaman O, et al. Protective effects of erdosteine on doxorubicin-induced hepatotoxicity in rats. Arch Med Res 2007; 38:380-5. (Pubitemid 46528559)
3. Cai C, Lothstein L, Morrison RR, Hofmann PA. Protection from doxorubicin-induced cardiomyopathy using the modified anthracycline N-benzyladriamycin-14-valerate (AD 198). J Pharmacol Exp Ther 2010; 335:223-30.
4. Koka S, Das A, Zhu SG, Durrant D, Xi L, Kukreja RC. Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect. J Pharmacol Exp Ther 2010; 334:1023-30.
5. Kim KH, Oudit GY, Backx PH. Erythropoietin protects against doxorubicin-induced cardiomyopathy via a phosphatidylinositol 3-kinase-dependent pathway. J Pharmacol Exp Ther 2008; 324:160-9. (Pubitemid 350294149)
6. Chen Y, Jungsuwadee P, Vore M, Butterfield DA, St. Clair DK. Collateral damage in cancer chemotherapy: oxidative stress in nontargeted tissues. Mol Interv 2007; 7:147-56. (Pubitemid 47026725)
7. Essick EE, Sam F. Oxidative stress and autophagy in cardiac disease, neurological disorders, aging and cancer. Oxid Med Cell Longev 2010; 3:168-77.
8. Karaman A, Fadillioglu E, Turkmen E, Tas E, Yilmaz Z. Protective effects of leflunomide against ischemia-reperfusion injury of the rat liver. Pediatr Surg Int 2006; 22:428-34.
9. Feng YQ, Zuo XL, Li RF, Zhang KJ, Chen F, Xiao H. [Protection against doxorubicin-induced oxidative damage in normal blood cells by naringenin]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2008; 16:790-3.
10. Kasapovic J, Pejic S, Stojiljkovic V, Todorovic A, Radosevic-Jelic L, Saicic ZS, et al. Antioxidant status and lipid peroxidation in the blood of breast cancer patients of different ages after chemotherapy with 5-fluorouracil, doxorubicin and cyclophosphamide. Clin Biochem 2010; 43:1287-93.
11. Bouayed J, Bohn T. Exogenous antioxidants - Double-edged swords in cellular redox state: Health beneficial effects at physiologic doses versus deleterious effects at high doses. Oxid Med Cell Longev 2010; 3:228-37.
12. Al-Rejaie SS, Aleisa AM, Al-Yahya AA, Bakheet SA, Alsheikh A, Fatani AG, et al. Progression of diethylnitrosamine-induced hepatic carcinogenesis in carnitinedepleted rats. World J Gastroenterol 2009; 15:1373-80.
13. Mohamad RH, El-Bastawesy AM, Zekry ZK, Al-Mehdar HA, Al-Said MG, Aly SS, et al. The role of Curcuma longa against doxorubicin (adriamycin)-induced toxicity in rats. J Med Food 2009; 12:394-402.
14. Lheureux PE, Hantson P. Carnitine in the treatment of valproic acid-induced toxicity. Clin Toxicol (Phila) 2009; 47:101-11.
15. Sayed-Ahmed MM, Darweesh AQ, Fatani AJ. Carnitine deficiency and oxidative stress provoke cardiotoxicity in an ifosfamide-induced Fanconi syndrome rat model. Oxid Med Cell Longev 2010; 3:266-74.
16. Augustyniak A, Skrzydlewska E. The influence of L-carnitine suplementation on the antioxidative abilities of serum and the central nervous system of ethanol-induced rats. Metab Brain Dis 2010.
17. Bodea F, Bocea A, Decea N. [L-carnitine decreases oxidative stress induced by experimental hypobaric hypoxia]. Pediatr Endocrinol Diabetes Metab 2010; 16:78-81.
18. Liu J. The effects and mechanisms of mitochondrial nutrient alpha-lipoic acid on improving age-associated mitochondrial and cognitive dysfunction: an overview. Neurochem Res 2008; 33:194-203. (Pubitemid 350242787)
19. Ozsoy S, Ozsoy B, Ozyildiz Z, Aytekin I. Protective effect of L-carnitine on experimental lead toxicity in rats: a clinical, histopathological and immunohistochemical study. Biotech Histochem 2010.
20. Chen HH, Sue YM, Chen CH, Hsu YH, Hou CC, Cheng CY, et al. Peroxisome proliferator-activated receptor alpha plays a crucial role in L-carnitine anti-apoptosis effect in renal tubular cells. Nephrol Dial Transplant 2009; 24:3042-9.
21. Crill CM, Helms RA. The use of carnitine in pediatric nutrition. Nutr Clin Pract 2007; 22:204-13.
22. Arduini A, Bonomini M, Savica V, Amato A, Zammit V. Carnitine in metabolic disease: potential for pharmacological intervention. Pharmacol Ther 2008; 120:149-56.
23. Borum PR. Carnitine in parenteral nutrition. Gastroenterology 2009; 137:129-34.
24. Karanth J, Jeevaratnam K. Effect of carnitine supplementation on mitochondrial enzymes in liver and skeletal muscle of rat after dietary lipid manipulation and physical activity. Indian J Exp Biol 2010; 48:503-10.
25. Mate A, Miguel-Carrasco JL, Vazquez CM. The therapeutic prospects of using L-carnitine to manage hypertension-related organ damage. Drug Discov Today 2010; 15:484-92.
26. Thangasamy T, Jeyakumar P, Sittadjody S, Joyee AG, Chinnakannu P. L-carnitine mediates protection against DNA damage in lymphocytes of aged rats. Biogerontology 2009; 10:163-72.
27. Jones LL, McDonald DA, Borum PR. Acylcarnitines: role in brain. Prog Lipid Res 2010; 49:61-75.
28. Morgante G, Scolaro V, Tosti C, Di Sabatino A, Piomboni P, De Leo V. [Treatment with carnitine, acetyl carnitine, l-arginine and ginseng improves sperm motility and sexual health in men with asthenopermia]. Minerva Urol Nefrol 2010; 62:213-8.
29. van der Meer PF. Platelet additive solutions: a future perspective. Transfus Clin Biol 2007; 14:522-5.
30. Tangpong J, Miriyala S, Noel T, Sinthupibulyakit C, Jungsuwadee P, St. Clair DK. Doxorubicin-induced central nervous system toxicity and protection by xanthone derivative of Garcinia Mangostana. Neuroscience 2010; In press.
31. Xu M, Sheng L, Zhu X, Zeng S, Chi D, Zhang GJ. Protective effect of tetrandrine on doxorubicin-induced cardiotoxicity in rats. Tumori 2010; 96:460-4.
32. Danz ED, Skramsted J, Henry N, Bennett JA, Keller RS. Resveratrol prevents doxorubicin cardiotoxicity through mitochondrial stabilization and the Sirt1 pathway. Free Radic Biol Med 2009; 46:1589-97.
33. Panjrath GS, Patel V, Valdiviezo CI, Narula N, Narula J, Jain D. Potentiation of Doxorubicin cardiotoxicity by iron loading in a rodent model. J Am Coll Cardiol 2007; 49:2457-64. (Pubitemid 46962267)
34. Andreadou I, Sigala F, Iliodromitis EK, Papaefthimiou M, Sigalas C, Aligiannis N, et al. Acute doxorubicin cardiotoxicity is successfully treated with the phytochemical oleuropein through suppression of oxidative and nitrosative stress. J Mol Cell Cardiol 2007; 42:549-58. (Pubitemid 46357553)
35. Firat O, Kirdok O, Makay O, Caliskan C, Yilmaz F, Ilgezdi S, et al. Can hyperbaric oxygenation decrease doxorubicin hepatotoxicity and improve regeneration in the injured liver? J Hepatobiliary Pancreat Surg 2009; 16:346-52.
36. Cosan D, Basaran A, Gunes HV, Degirmenci I, Aral E. The effect of doxorubicin on rats that received toxic and carcinogenic benzo(a)pyrene. Folia Histochem Cytobiol 2008; 46:367-72.
37. Laub MC, Paetzke-Brunner I, Jaeger G. Serum carnitine during valproic acid therapy. Epilepsia 1986; 27:559-62. (Pubitemid 16026053)
38. Fujita M, Nakanishi T, Shibue Y, Kobayashi D, Moseley RH, Shirasaka Y, et al. Hepatic uptake of gamma-butyrobetaine, a precursor of carnitine biosynthesis, in rats. Am J Physiol Gastrointest Liver Physiol 2009; 297:681-6.
39. Hwu WL, Chien YH, Tang NL, Law LK, Lin CY, Lee NC. Deficiency of the carnitine transporter (OCTN2) with partial N-acetylglutamate synthase (NAGS) deficiency. J Inherit Metab Dis 2007; 30:816.
40. Chang B, Nishikawa M, Nishiguchi S, Inoue M. L-carnitine inhibits hepatocarcinogenesis via protection of mitochondria. Int J Cancer 2005; 113:719-29. (Pubitemid 40101252)
41. Koc A, Duru M, Ciralik H, Akcan R, Sogut S. Protective agent, erdosteine, against cisplatin-induced hepatic oxidant injury in rats. Mol Cell Biochem 2005; 278:79-84. (Pubitemid 41418922)
42. Sayed-Ahmed MM, Aleisa AM, Al-Rejaie SS, Al-Yahya AA, Al-Shabanah OA, Hafez MM, et al. Thymoquinone attenuates diethylnitrosamine induction of hepatic carcinogenesis through antioxidant signaling. Oxid Med Cell Longev 2010; 3:254-61.
43. Fisher-Wellman K, Bell HK, Bloomer RJ. Oxidative stress and antioxidant defense mechanisms linked to exercise during cardiopulmonary and metabolic disorders. Oxid Med Cell Longev 2009; 2:43-51.
44. Injac R, Perse M, Cerne M, Potocnik N, Radic N, Govedarica B, et al. Protective effects of fullerenol C60(OH)24 against doxorubicin-induced cardiotoxicity and hepatotoxicity in rats with colorectal cancer. Biomaterials 2009; 30:1184-96.
45. Kalender Y, Yel M, Kalender S. Doxorubicin hepatotoxicity and hepatic free radical metabolism in rats. The effects of vitamin E and catechin. Toxicology 2005; 209:39-45.
46. Yapar K, Kart A, Karapehlivan M, Atakisi O, Tunca R, Erginsoy S, et al. Hepatoprotective effect of L-carnitine against acute acetaminophen toxicity in mice. Exp Toxicol Pathol 2007; 59:121-8. (Pubitemid 47405222)
47. El-Awady ES, Moustafa YM, Abo-Elmatty DM, Radwan A. Cisplatin-induced cardiotoxicity: Mechanisms and cardioprotective strategies. Eur J Pharmacol 2010.
48. Sayed-Ahmed MM, Aleisa AM, Al-Rejaie SS, Al-Yahya AA, Al-Shabanah OA, Hafez MM, Nagi MN. Thymoquinone attenuates diethylnitrosamine induction of hepatic carcinogenesis through antioxidant signaling. Oxid Med Cell Longev 2010; 3:254-61.
49. Kolodziejczyk J, Saluk-Juszczak J, Wachowicz B. L-carnitine protects plasma components against oxidative alterations. Nutrition 2010.
50. Zekri AR, Hafez MM, Bahnassy AA, Hassan ZK, Mansour T, Kamal MM, et al. Genetic profile of Egyptian hepatocellular-carcinoma associated with hepatitis C virus Genotype 4 by 15 K cDNA microarray: preliminary study. BMC Res Notes 2008; 1:106.
51. Alhomida AS. Study of the effects of theophylline-related changes in total, free, short-chain acyl and long-chain acyl carnitine concentrations in rat heart. Toxicology 1997; 121:205-13. (Pubitemid 27296747)
52. Cao Y, Wang YX, Liu CJ, Wang LX, Han ZW, Wang CB. Comparison of pharmacokinetics of L-carnitine, acetyl-L-carnitine and propionyl-L-carnitine after single oral administration of L-carnitine in healthy volunteers. Clin Invest Med 2009; 32:13-9.
53. Lawrence RA, Burk RF. Glutathione peroxidase activity in selenium-deficient rat liver. Biochem Biophys Res Commun 1976; 71:952-8.
54. Pljesa-Ercegovac M, Mimic-Oka J, Dragicevic D, Savic-Radojevic A, Opacic M, Pljesa S, et al. Altered antioxidant capacity in human renal cell carcinoma: role of glutathione associated enzymes. Urol Oncol 2008; 26:175-81. (Pubitemid 351291691)
55. Habig WH, Pabst MJ, Jakoby WB. Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. J Biol Chem 1974; 249:7130-9.
56. Sun Y, Oberley LW, Li Y. A simple method for clinical assay of superoxide dismutase. Clin Chem 1988; 34:497-500.
57. Durak I, Yurtarslanl Z, Canbolat O, Akyol O. A methodological approach to superoxide dismutase (SOD) activity assay based on inhibition of nitroblue tetrazolium (NBT) reduction. Clin Chim Acta 1993; 214:103-4. (Pubitemid 23055374)